Merrimack has developed a broad intellectual property position around its oncology therapeutic portfolio, including MM121. This portfolio includes U.S. and international patent filings relating to compositions of matter and methods of use as well as licensed patents and pending patent applications, trade secrets and proprietary know-how.
MM-121 is a monoclonal antibody designed to block signaling of the ErbB3 receptor, a receptor in the ErbB family, a pathway that plays a critical role in cancer signaling. Upon initiation of the Phase 1 trial, MM-121 becomes the first systems biology product as well as the first selective ErbB3 antagonist to enter human clinical development. Preclinical data exhibiting MM-121's impact on multiple cancer models (including lung, ovarian, breast, prostate and renal) were presented at the annual meeting of the American Association for Cancer Research in April 2008. The Phase 1 trial is being conducted at 3 centers in the United States.
Merrimack Pharmaceuticals, Inc., is a biotechnology company focused on
the discovery, design and development of novel treatments for diseases in
the areas of autoimmunity and cancer. Its autoimmune candidate, MM-093, is
currently in Phase 2 clinical development. Its first oncology product,
MM-121 is currently in Phase 1 clinical development. MM-093 and MM-121 are
investigational drugs and have not been approved by the U.S. Food and Drug
Administration or any international regulatory agency. The company's
proprietary Network Biology discovery platform, developed with the help of
leading scientists from MIT and Harvard, enables the high throughput
profiling of protein networks as a basis for improved validation, lead
identification and speed in the development of innovative therapeutics.
|SOURCE Merrimack Pharmaceuticals, Inc.|
Copyright©2008 PR Newswire.
All rights reserved